EP-2025: The potential role of gold nanoparticles in proton beam radiosurgery for arteriovenous malformations  by Nor, A. et al.
S956                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
Purpose or Objective: Hyperthermia (raising the tumour 
temperature to 40-43°C) is an effective treatment in 
combination with radiotherapy for several tumour sites, 
including cervical cancer, which is mainly caused by infection 
with the Human Papillomavirus (HPV). The aim of our study is 
to improve treatment strategies for cervical carcinoma by 
(#1) unravelling mechanisms of hyperthermia induced 
radiosensitization, (#2) optimization of time interval between 
hyperthermia and radiotherapy and (#3) investigating the 
benefit of additional treatments. 
 
Material and Methods: HPV-positive cervical cell lines SiHa 
and HeLa were used. Cells were treated with (#1) 
hyperthermia alone (42˚C for 1h), (#2) hy perthermia and 
irradiation in different time intervals between the two 
therapies and (#3) hyperthermia and radiation with 
additional agents PARP1-inhibitor (i.e. a drug blocking a DNA 
repair protein) and cisplatin. Clonogenic survival assays and 
γH2AX stainings (a staining to visualize DNA double strand 
breaks) were carried out in order to determine the 
effectiveness of the (combined) treatments. Protein levels of 
p53 and DNA repair proteins were investigated using western 
blot. Apoptosis was measured in cell lines using the Nicoletti 
assay and cell cycle distribution was analyzed using the BrdU-
assay. 
 
Results: (#1) The high-risk HPV types 16 and 18 produce the 
oncoprotein, early protein 6 (E6), which binds to p53 before 
both proteins get degraded. Therefore, p53 cannot induce 
cell cycle block nor apoptosis, limiting the radiation effects. 
Hyperthermia increases the effectiveness by preventing the 
formation of the E6-p53 complex, rescuing p53 from 
degradation, resulting into functional p53 causing apoptosis 
and cell cycle arrest. (#2) Higher levels of p53 are present 
immediately after hyperthermia and remain up to four hours 
after treatment. The main therapy, radiotherapy or 
chemotherapy, should be applied within this time frame to 
yield a beneficial effect. (#3) Combination treatment of 
radiotherapy, hyperthermia, cisplatin and PARP1-inhibitors 
resulted in a lower survival fraction due to an increased 
number of DNA double strand breaks as compared to 
radiation alone. Cisplatin and PARP1-inhibition significantly 
enhanced the combined hyperthermia/radiation treatment. 
 
 
 
 
Conclusion: Our findings provide new insights for patients 
suffering from HPV-positive cervical cancer. Hyperthermic-
radiosensitization, makes radiotherapy significantly more 
effective by rescuing p53 from getting degraded. Adding 
PARP1-inhibitor or cisplatin further improves the 
effectiveness of hyperthermic-radiosensitization, which will 
increase clinical outcomes substantially.  
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Purpose or Objective: To theoretically evaluate therapeutic 
gain from radiation dose enhancement by gold nanoparticles 
(AuNP) based on their physical interaction with protons.  
 
Material and Methods: Nanoparticles range in size from 1 x 
10⁻⁹m to 100 x 10⁻⁹m, and exert their effect by either 
entering the cell, or by attaching to the cell membrane 
surface. Radiation enhancement by gold nanoparticles (AuNP) 
is based on the generation of much localized secondary 
radiation when irradiated. This results in a Dose Enhancment 
Factor (DEF) and has been well described for photon 
irradiation and is most pronounced with kilo voltage photons, 
but happens also with Mega Voltage (MeV). For protons the 
DEF obtained with metallic nanoparticles has recently been 
studied. We took the definition of DEF as being: DEF=( Dpure 
+ DGNP – Dwnp )/ Dpure , where Dpure is the dose deposited 
in pure water.  
 
Results: In vivo studies on tumors in mice have shown a 
considerable delay in tumor growth for mice receiving AuNPs 
with protons compared to protons alone. Protons have a high 
cross-section for gold over a large range of clinical energies, 
and the interaction produces Auger electrons with a very 
short range. The sphere of DEF around the AuNP is influenced 
by its size. For an AuNP of r = 22nm and 80 MeV protons the 
radius of the sphere of DEF is in the order of 18nm, with dose 
enhancement factors of up to 2 described. We obtained a 
value of 1.06 at 1 nm from a nanoparticle with radius 25 nm 
and taking Dpure as being: Dpure [Gy] ≈ 8.16 x Sw [ MeV x 
cm2/g ], where Sw is the stopping power of water. This small 
radius means that in order to be effective the AuNPs need to 
be in very close contact with the target. In the treatment of 
AVMs the prime target is the endothelial cell. Angiogenesis 
occurring in AVMs is driven by endothelial cells stimulated by 
vascular angiogenic factors binding on cell membrane 
receptors. AVM endothelial cells over express these receptors 
compared to their counterparts in normal brain vessels. IMC-
1121B, a human antibody to VEGFReceptor2, when linked 
with an AuNP has the potential to selectively increase the 
local AuNP concentration on the membrane of AVM 
endothelial cells. For conventional dose/fractionation 
schedules the radiobiological effects are governed by DNA 
damage in the cell nucleus. Membrane location could also be 
exploited because a cell membrane initiated effect is 
described, whereby activation of the acid 
sphingomyelinase/ceramide pathway occurs after doses >10 
Gy, leading to endothelial apoptosis. 
 
Conclusion: Successful AVM radiosurgery is amongst others 
dose dependent. Therapeutic gain in proton radiosurgery is 
possible with AuNP-VEGFR2ab located on the cell membrane, 
combined with doses > 10 Gy. This approach needs to be 
researched further, but offers the possibility for better 
obliteration rates and/or shorter latent intervals.  
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Purpose or Objective: Soft-tissue sarcomas (STS) are 
aggressive tumours with a poor prognosis and there is a major 
clinical need for novel strategies. Poly-ADP ribose polymerase 
(PARP)-1 promotes base excision repair and DNA strand break 
repair. Inhibitors of PARP (PARPi) have shown to enhance the 
cytotoxic effect of irradiation (IR), and evidences suggest 
that PARPi could be used to selectively kill cancers defective 
in DNA repair. Sarcomagenesis is linked to aberrant biological 
pathways and some STS have defect in DNA repair systems, so 
there is a rationale for using PARPi in STS. We investigated 
the effect of PARP inhibition on STS cell lines survival after IR 
and on radiation-induced DNA damage foci. 
